BPC-157 (Peptides, Part 2): What the Evidence Shows The compound is unapproved by the FDA, the demand is real, and the clinical reasoning that sits between those two facts Two distinct biological profiles depending on how its taken, a regulatory classification that places it outside standard compounding protections, and an internet reputation that outpaces both
This peptide has the same potency as semaglutide at the GLP-1 receptor, but only about half the potency at GIP as tirzepatide
If youve shaken it hard, its unfortunately best to discard it to ensure the integrity of your study
Clin Park Relat Disord
Oguztuzun S, Abu-Hijleh A, Coban T, et al
Something in it was doing that work, and that something turned out to be GHK